ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0510

Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct (MAA) And/or Citrulline (CIT) Induces Unique Cellular Responses in Human RA Synoviocytes

Brittany Wordekemper, Nozima Aripova, Michael Duryee, Eric Daubach, Bryant England, James O'Dell, Ted Mikuls and Geoffrey Thiele, University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2021

Keywords: cytokines, Fibroblasts, Synovial, Innate Immunity Rheumatic Disease, Osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Session Title: Cytokines & Cell Trafficking Poster (0508–0516)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Malondialdehyde (MDA) is produced in response to oxidative stress and is associated with inflammation and disease pathogenesis. MDA can break down and form acetaldehyde (AA). Together MDA and AA can non-enzymatically combine to create a stable protein adduct termed malondialdehyde-acetaldehyde adduct (MAA), which is strongly immunogenic, even in the absence adjuvant. Our group showed that MAA modified proteins are present in Rheumatoid Arthritis (RA) synovium and co-localize with citrullinated (CIT) antigens known to be strongly associated with the pathogenesis of RA. RA synovium is characterized by a combination of pro-inflammatory and pro-fibrotic signals secreted by immune cells and resident human fibroblast-like synoviocytes (HFLS). The purpose of this study is to evaluate pro-inflammatory and pro-fibrotic signals released by HFLS from patients with RA (HFLS-RA) vs. HFLS from patients with osteoarthritis (HFLS-OA) when stimulated with an extracellular matrix protein fibrinogen (Fib) modified with MAA, CIT, or the combination of MAA-CIT.

Methods: The HFLS-RA and HFLS-OA cell lines were cultured for 24 hours in the presence of 25 µg/mL of; unmodified Fib or Fib modified with MAA, CIT, or MAA-CIT. Supernatants were collected and analyzed by ELISA using the Meso Scale Diagnostics (MSD) platform for the release of pro-inflammatory and pro-fibrotic markers.

Results: Compared to HFLS-OA cells, HFLS-RA cells stimulated with Fib-MAA-CIT (Figures 1 and 2) significantly increased the secretion of vimentin and IL-4 (pro-fibrotic markers), and IL-6, IL-8, and MCP-1 (pro-inflammatory markers). HFLS-RA cells stimulated with Fib-CIT showed significantly increased levels of only the pro-inflammatory markers; IL-6 and MCP-1 (Figure 2) as compared to HFLS-OA cells. Additionally, HFLS-RA cells stimulated with Fib-MAA showed significantly increased secretions of the pro-inflammatory marker IL-8 (Figure 2B) compared to HFLS-OA cells.

Conclusion: These studies demonstrate that HFLS-RA cells secreted significantly increased pro-inflammatory and/or pro-fibrotic markers when compared to HFLS-OA cells depending on whether fibrinogen was modified with MAA, CIT or MAA-CIT. Additionally, these data also suggest that the HFLS-RA cells developed unique cellular responses compared to OA cells, making them useful in understanding how these modified proteins affect HFLS cells. Thus, further studies will evaluate the effects of other extracellular proteins that have been implicated in the pathogenesis of RA, and modified with MAA, CIT or MAA-CIT on the expression of pro-inflammatory and pro-fibrotic markers.

Figure 1. Pro-fibrotic factors release from stimulated HFLS-RA cells. HFLS-RA cells were incubated with Fibrinogen modified antigens. Afterwards, the supernatants were collected for analysis of: IL_4 (A) and vimentin (B) release using Mesoscale Discovery assay kit. The concentration of all cytokines was measured in ng/mL. p<0.001 significantly different from all OA cell antigen treatments. n=4

Figure 2. Pro-inflammatory cytokines release from stimulated HFLS-RA cells. HFLS-RA cells were incubated with Fibrinogen modified antigens. Afterwards, the supernatants were collected for analysis of: IL-6 (A), IL-8 (B), and MCP_1 (C) release using Mesoscale Discovery assay kit. The concentration of all cytokines was measured in ng/mL. p<0.05 significantly different from OA cells treated with Fib-Cit. p<0.05 significantly different from OA cells treated with Fib-MAA-CIT. n=4


Disclosures: B. Wordekemper, None; N. Aripova, None; M. Duryee, None; E. Daubach, None; B. England, Boehringer-Ingelheim, 2; J. O'Dell, None; T. Mikuls, Gilead Sciences, 2, Horizon, 2, 5, Pfizer Inc, 2, Sanofi, 2, Bristol-Myers Squibb, 2; G. Thiele, Regeneron, 6.

To cite this abstract in AMA style:

Wordekemper B, Aripova N, Duryee M, Daubach E, England B, O'Dell J, Mikuls T, Thiele G. Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct (MAA) And/or Citrulline (CIT) Induces Unique Cellular Responses in Human RA Synoviocytes [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/fibrinogen-modified-with-malondialdehyde-acetaldehyde-adduct-maa-and-or-citrulline-cit-induces-unique-cellular-responses-in-human-ra-synoviocytes/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fibrinogen-modified-with-malondialdehyde-acetaldehyde-adduct-maa-and-or-citrulline-cit-induces-unique-cellular-responses-in-human-ra-synoviocytes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences